Dr. Shawn Zimberg

Shawn Zimberg, MD

National Director of Radiation Oncology Services, Solaris Health

Dr. Zimberg is a leading authority with over 25 years of experience in the strategic business development and management of radiation oncology practices, and financial and clinical optimization of multi-site and regional oncology facilities.

Dr. Zimberg was a founding partner of Integrated Medical Professionals, PLLC, a Solaris Health affiliate practice, and since 2006 has served a board member of IMP and Medical Director of its Advanced Radiation Centers of New York division.   Under his leadership, ARC has become the largest freestanding radiation oncology practice in the Metro New York Tri-State Region, and has developed an infrastructure and service line that provides physics, dosimetry and IT support to oncology practices across the nation.

Over his career, Dr. Zimberg has been at the forefront of deploying sophisticated radiation oncology technologies for brain, lung, head and neck, and prostate cancer treatments.  Dr. Zimberg has co-authored numerous peer-reviewed medical journal publications ranging from new technologies in the treatment of prostate cancer to medical economics of large group practice, and has been a principal investigator in clinical trials including several FDA pivotal trials evaluating cutting-edge technologies in cancer care.   He is routinely listed in Castle Connolly Regional Top Doctors in the New York area.

Dr. Zimberg received a BS degree from the University of Michigan, a MD degree from the University of Michigan Medical School, and completed his radiation oncology residency at Memorial Sloan-Kettering Cancer Center, where he was received the American Cancer Society’s Clinical Fellowship award.  He serves on the board of directors of the Association of Free-standing Radiation Oncology Centers (AFROC), and is a member of the Investment Advisory Board of Evolution Venture Partners, a healthcare investment bank focusing on biotechnology and life-sciences including oncology and cancer breakthroughs.